Mirum Pharmaceuticals’ Atebrioz (atebrioz) has won FDA approval for fibrodysplasia ossificans progressiva (FOP), adding a third approved therapy for the ultra-rare condition. Mirum acquired Atebrioz from Incyte earlier this year, positioning the company to build on the existing FOP treatment footprint. The new approval matters because FOP patients face progressive soft-tissue-to-bone conversion with limited intervention options. An oral pill format can also influence real-world adoption versus more complex dosing schedules used in the category. For Mirum, FDA approval creates immediate commercial and clinical momentum around Atebrioz, while also sharpening competitive differentiation against the two other FDA-approved FOP therapies already on the market.